| 000 | 01695 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517135012.0 | ||
| 264 | 0 | _c20170710 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a0392-856X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLeon, Leticia | |
| 245 | 0 | 0 |
_aLong-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. _h[electronic resource] |
| 260 |
_bClinical and experimental rheumatology _c |
||
| 300 |
_a165-170 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aGiant Cell Arteritis _xdiagnosis |
| 650 | 0 | 4 |
_aGlucocorticoids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 | _aPatient Safety |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSpain |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRodriguez-Rodriguez, Luis | |
| 700 | 1 | _aFreites, Dalifer | |
| 700 | 1 | _aArietti, Lucia | |
| 700 | 1 | _aMorado, Inmaculada | |
| 700 | 1 | _aVadillo, Cristina | |
| 700 | 1 | _aLamas, José Ramón | |
| 700 | 1 | _aFernandez, Benjamin | |
| 700 | 1 | _aJover, Juan Angel | |
| 700 | 1 | _aAbasolo, Lydia | |
| 773 | 0 |
_tClinical and experimental rheumatology _gvol. 35 Suppl 103 _gno. 1 _gp. 165-170 |
|
| 999 |
_c26829319 _d26829319 |
||